Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Atigotatug/Nivolumab · BMS-986489

Monoclonal antibody · Immune activation, directed at fucosyl-GM1 and PD-1 (PDCD1) · developed by BRISTOL MYERS SQUIBB

Phase 1 Most advanced trial (none active)

BMY Developer

1 Registered trials

What is Atigotatug/Nivolumab?

Atigotatug/nivolumab is a fixed-dose combination of two monoclonal antibodies: atigotatug (anti-fucosyl-GM1) and nivolumab (anti-PD-1). Atigotatug binds fucosyl-GM1 on cancer cells to activate antibody-dependent and complement-dependent cytotoxicity. Nivolumab blocks PD-1 to prevent immune checkpoint inhibition and activate T-cell responses. The combination is studied in small cell lung carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: BMS-986489
Drug type: Monoclonal antibody
Targets: fucosyl-GM1, PD-1 (PDCD1), PD-L1 (CD274) (secondary target), PD-L2 (PDCD1LG2) (secondary target)
Mechanism: Immune activation, directed at fucosyl-GM1 and PD-1 (PDCD1)
Pathways: T-cell activation, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity
Therapy area: Oncology
Developer: BRISTOL MYERS SQUIBB (BMY)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06799286	Phase 1	Small Cell Lung Carcinoma	Completed	BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Small Cell Lung Carcinoma

Other drugs acting on PDCD1

Berahyaluronidase Alfa and Pembrolizumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Balstilimab Phase 2/3 BPT567 Phase 1 Budigalimab Phase 2/3 Cadonilimab Early Phase 1 CDX-585 Phase 1 CTX-8371 Phase 1 Geptanolimab Phase 1/2 Ivonescimab Phase 3

More from BRISTOL MYERS SQUIBB

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Atigotatug/Nivolumab

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z